Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis
197 Followers
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.67 - $18.07
Previous Close$14.98
Volume630.09K
Average Volume (3M)1.19M
Market Cap
$1.31B
Enterprise Value$991.46M
Total Cash (Recent Filing)$317.94M
Total Debt (Recent Filing)$300.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 06, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding87,389,859
10 Day Avg. Volume923,038
30 Day Avg. Volume1,187,449
Standard Deviation0.35
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.55
Forecast
1Y Price Target
$41.78Price Target Upside178.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Secures Major Cancer Drug Rights
PremiumCompany Announcements
Day One Biopharmaceuticals Updates FIREFLY-2 Trial Strategy
Bulls Say, Bears Say
Bulls Say
Financial StrengthDAWN has a cash balance of approximately $417.8 million pro forma following the sale of its Priority Review Voucher, indicating strong financial strength.
Pipeline ExpansionDay One Biopharmaceuticals expanded their pipeline with a PTK7 targeted ADC, acquired from MabCare Therapeutics.
Regulatory ApprovalThe FDA cleared the IND application for DAY301, allowing Day One to start dosing patients with solid tumors in the Phase 1/2a trial.
Bears Say
Financial PerformanceThe company’s burn rate and cash position have been an increasing focus, with concerns about the possibility of a raise if the early Ojemda launch is slower than expected.
Market DynamicsAround 90% of the target market is the prevalent population who are already on existing treatment options.
Safety ConcernsGrowth deceleration was an unexpected toxicity observed in an investigator-sponsored trial study in pLGG patients.
---
Ownership Overview
56.10% Insiders
20.47% Mutual Funds
11.33% Other Institutional Investors
12.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.67 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 16 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on May 06, 2024. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.057.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.73.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,389,860 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went up 2.892%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 129M.
---
Day One Biopharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.78 (178.91% Upside)
$41.78 (178.91% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 497.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $131.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.69%
12-Months-Change
Fundamentals
Return on Equity
-69.97%
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Stock 12 Month Forecast
Average Price Target
$41.78
▲(178.91% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Karyopharm Therapeutics
―
Mersana Therapeutics
―
Molecular Templates
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
-4.01%
assigned a buy rating last month
Copying Soumit Roy's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of -4.01% per trade.
---